268 related articles for article (PubMed ID: 33287740)
1. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
Yan S; Fang J; Chen Y; Xie Y; Zhang S; Zhu X; Fang F
BMC Cancer; 2020 Dec; 20(1):1205. PubMed ID: 33287740
[TBL] [Abstract][Full Text] [Related]
2. Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes.
Shen X; Gu X; Ma R; Li X; Wang J
Front Cell Dev Biol; 2022; 10():772701. PubMed ID: 35372348
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.
Nie X; Tan J
Hereditas; 2022 Mar; 159(1):17. PubMed ID: 35303965
[TBL] [Abstract][Full Text] [Related]
4. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
5. A novel extrachromosomal circular DNA related genes signature for overall survival prediction in patients with ovarian cancer.
Zhang Y; Dong K; Jia X; Du S; Wang D; Wang L; Qu H; Zhu S; Wang Y; Wang Z; Zhang S; Sun W; Fu S
BMC Med Genomics; 2023 Jun; 16(1):140. PubMed ID: 37337170
[TBL] [Abstract][Full Text] [Related]
6. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract][Full Text] [Related]
7. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
Front Immunol; 2021; 12():768115. PubMed ID: 34966389
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
9. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Wu M; Gu S; Xu S; Wu Y; Wang Y
J Ovarian Res; 2023 Apr; 16(1):86. PubMed ID: 37120633
[TBL] [Abstract][Full Text] [Related]
10. Immune Subtype Profiling and Establishment of Prognostic Immune-Related lncRNA Pairs in Human Ovarian Cancer.
Wang X; Wang J; Yu M
Comput Math Methods Med; 2022; 2022():8338137. PubMed ID: 35578596
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
12. The Interaction between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer.
Sheng D; Yue K; Li H; Zhao L; Zhao G; Jin C; Zhang L
Microbiol Spectr; 2023 Mar; 11(2):e0354922. PubMed ID: 36975828
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract][Full Text] [Related]
14. A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.
Zhu L; Lin Z; Wang K; Gu J; Chen X; Chen R; Wang L; Cheng X
Front Endocrinol (Lausanne); 2024; 15():1372413. PubMed ID: 38529390
[TBL] [Abstract][Full Text] [Related]
15. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
16. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J; Vankerckhoven A; Vanmeerbeek I; Borras DM; Berckmans Y; Wouters R; Laureano RS; Baert T; Boon L; Landolfo C; Testa AC; Fischerova D; Van Holsbeke C; Bourne T; Chiappa V; Froyman W; Schols D; Agostinis P; Timmerman D; Tejpar S; Vergote I; Coosemans A; Garg AD
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795003
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinoma immune-related microRNA affects the heterogeneity of the endocrine microenvironment and anti-tumor immune pattern.
Gao K; Wang Q; Xiang P; Xiong J; Xu X; Qin L; Sun X; Fan Y; Yue C
J Gene Med; 2024 Jan; 26(1):e3602. PubMed ID: 37813677
[TBL] [Abstract][Full Text] [Related]
18. Identification of Immune-Related Key Genes in Ovarian Cancer Based on WGCNA.
Quan Q; Xiong X; Wu S; Yu M
Front Genet; 2021; 12():760225. PubMed ID: 34868239
[No Abstract] [Full Text] [Related]
19. System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer.
Shi T; Yan R; Han MI
Oncol Res; 2023; 31(4):591-604. PubMed ID: 37415732
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
